Increase in Share Capital and Listing of New B-shares resulting from Euroclone Acquisition

Biohit Oyj May 22, 2013 at 9 A.M. local time (EET)

A total of 180,000 new B-shares of Biohit Oyj have been subscribed for based on Biohit Oyj's Euroclone acquisition. The corresponding increase in the company's share capital is EUR 30,600. The increase has been registered with the Finnish Trade Register on May 16, 2013. The company has requested NASDAQ OMX Helsinki Ltd. to list the new shares for public trading as of May 22, 2013. In terms of shareholder rights, the new B-shares are identical to the B-shares of the company already traded on NASDAQ OMX Helsinki Ltd.

As a result of new shares, the total number of Biohit shares raises up to 13,795,593 shares (13,615,593) and the number of B-shares to 10,820,093 shares (10,640,093). The company's share capital will increase from 2,314,650.81 euros to 2,345,250.81 euros.

Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.